Abstract 514: Novel potent azetidine-based inhibitors bind irreversibly to Stat3 DNA-binding domain (DBD) and are efficacious against tumor growth in mice
Yue Chen(Cedars-Sinai Medical Center), James Turkson(Cedars-Sinai Medical Center), Ning Zhai(Cedars-Sinai Medical Center), Yinsong Zhu(Cedars-Sinai Medical Center), Kayo Nakamura(University of Hawaiʻi at Mānoa), Marcus A. Tius(University of Hawaiʻi at Mānoa), Peibin Yue(University of Central Florida), Nagendra Verma(St. Cloud State University), Wen‐Zhen Fu(Zhengzhou University), Francisco Lopez‐Tapia(Cedars-Sinai Medical Center), Weiliang Chen(University of Hawaiʻi at Mānoa), Christine Brotherton‐Pleiss(University of Hawaiʻi at Mānoa)
Cited by 0
Related Papers
Substrate and Functional Diversity of Lysine Acetylation Revealed by a Proteomics Survey
|Molecular Cell|2006|1.5k
Acetylation Is Indispensable for p53 Activation
|Cell|2008|828
STAT3 as a target for inducing apoptosis in solid and hematological tumors
|Cell Research|2008|489
Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity, Gene Regulation, and Cell Transformation
|Journal of Biological Chemistry|2001|437
Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts
|Proceedings of the National Academy of Sciences|2012|347